Wiser Choices in Osteoporosis Choice II: A Decision Aid for Patients and Clinicians
| Status: | Completed |
|---|---|
| Conditions: | Osteoporosis, Orthopedic, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Rheumatology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 50 - 90 |
| Updated: | 4/21/2016 |
| Start Date: | May 2009 |
| End Date: | February 2011 |
Wiser Choices In Osteoporosis Choice II
Emphasis in treating osteoporosis has been on T-scores rather than overall fracture risk.
Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis
treatment by providing an absolute fracture risk. FRAX combined with a decision aid may
promote a shared decision making approach with patients, allowing the clinician and patient
to weigh potential fracture risk (without treatment), versus risk reduction with medication
(including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:
- FRAX
- FRAX + decision aid
- Usual care (no decision aid and no FRAX given to clinician)
Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis
treatment by providing an absolute fracture risk. FRAX combined with a decision aid may
promote a shared decision making approach with patients, allowing the clinician and patient
to weigh potential fracture risk (without treatment), versus risk reduction with medication
(including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:
- FRAX
- FRAX + decision aid
- Usual care (no decision aid and no FRAX given to clinician)
Inclusion Criteria:
- Peri and Postmenopausal Caucasian, Black, Hispanic and Asian women, aged 50-90
- Bone mineral density (BMD) T-Score < 1.0
- Have appointment with clinician to discuss test results and treatment options
- Patients with FRAX <20% risk who have taken a bisphosphonate for < 5 years.
Exclusion Criteria:
- Unable to speak or read English
We found this trial at
1
site
Click here to add this to my saved trials
